GreenSpace Labs posts positive Phase 2 pilot data for CBD IBS drug

GreenSpace Labs said preliminary Phase 2 pilot data for GSL-01-001 showed symptom and quality-of-life improvements in IBS patients over 12 weeks. The company is now preparing a larger Phase 2 program and is seeking a pharma partner ahead of a 2028–2029 wave of branded IBS patent expirations. Why it matters: - GreenSpace Labs is aiming at a large IBS market it says exceeds $3.6 billion and is growing about 9% a year. - The company is positioning GSL-01-001 for a 2028–2029 patent cliff that could open space for new therapies as branded drugs lose exclusivity. - The drug candidate is designed to address IBS pain directly, a gap GreenSpace Labs says current approved therapies do not fill. What happened: - GreenSpace Labs announced preliminary Phase 2 pilot results for GSL-01-001, an oral cannabidiol-based therapy for irritable bowel syndrome. - The 12-week, single-site study enrolled 23 adult IBS patients. - Thirteen participants completed the full treatment period. - The company collected data through electronic capture, patient diaries and site-administered questionnaires. The details: - Average weekly scores for pain, discomfort, bloating, cramping and nausea declined from baseline through week 12. - Pain and discomfort fell from roughly 4.0 to 4.5 at baseline to about 1.5 to 2.0 by the final study weeks on a 5-point scale. - Bristol Stool Form Scale scores stayed in the normal range at about 4.0 throughout the study. - That pattern suggests bowel function did not worsen during the pilot. - The share of participants reporting IBS symptoms affected them “Extremely” or “Quite a Bit” fell from 51% at baseline to 10% by week 8. - The share reporting minimal or no impact rose from 32% at baseline to 73% at week 8. - No participants rated their overall health as “Excellent” or “Very Good” at baseline. - By week 12, six participants rated their health as “Very Good” or “Excellent.” Between the lines: - GreenSpace Labs is framing the pilot as hypothesis-generating, not ready for registration. - CEO William Albro said the directional trend across symptom domains matched the company’s mechanistic hypothesis and that the pilot would inform protocol improvements for a GCP-compliant Phase 2 program. - The company is also trying to differentiate its cannabinoid approach from olorinab, a single-mechanism CB2 agonist that failed to show efficacy in Pfizer/Arena’s Phase 2b CAPTIVATE trial. - GreenSpace Labs says GSL-01-001 uses a multi-target cannabinoid approach that engages multiple parts of the gut-brain axis. What’s next: - GreenSpace Labs plans to implement protocol changes before advancing to a larger Phase 2 program. - The company is targeting execution aligned with the 2028–2029 IBS patent cliff. - GreenSpace Labs is seeking a mid- to large-cap pharma partner with cannabinoid or GI franchise experience. - The company is considering exclusive worldwide licensing, co-development or full acquisition. - GreenSpace Labs says GSL-01-001 could eventually expand into IBD-associated pain, functional dyspepsia and post-infectious GI pain syndromes. The bottom line: - GreenSpace Labs has early pilot data that point to symptom relief without obvious stool-consistency tradeoffs, but the program still needs stronger clinical proof before it can compete in IBS commercialization.